Psoriasis
1,154
87
118
794
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
317 trials with published results (27%)
Research Maturity
794 completed trials (69% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
5.2%
60 terminated out of 1154 trials
93.0%
+6.4% vs benchmark
28%
318 trials in Phase 3/4
40%
317 of 794 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 794 completed trials
Clinical Trials (1154)
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)
Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis
Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity
A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)
Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis Treated With Narrowband UVB Phototherapy (CERAMOL PSOR CREMA)
Evidencing Vibroacoustic Sensing for Inflammatory Skin Disease Monitoring
A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice
Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
Comparative Study on Unani Formulation Vs Active Control in Plaque Psoriasis
Psoriasis Longitudinal Assessment and Registry
A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
Patient Study to Evaluate the Safety and Emollient Performance of Doublebase Once in the Treatment of Psoriasis